v3.25.4
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
REVENUE            
Gross Receipts $ 1,941   $ 1,941      
Net revenue 1,941 1,941    
COST OF REVENUE            
Cost of goods sold 1,057 1,057    
Gross Profit 884 884    
OPERATING EXPENSES            
Research and development 207,899 7,000 823,879 28,000    
Sales and marketing 425,489 16,678 696,639 104,344    
General and administrative expenses 512,993 191,578 15,982,233 410,805    
Total operating expenses 1,146,381 215,256 17,502,751 543,149    
Loss from operations (1,145,497) (215,256) (17,501,867) (543,149)    
Other income (expense):            
Interest expense (1,480,058) (2,297,882)    
Change in fair value of derivative liability 775,062 390,744    
Loss on extinguishment of debt (364,109)    
Total other (expense) income, net (704,996) (2,271,247)    
Income tax expense (1,013) (1,013)    
Net loss $ (1,850,493) $ (216,269) $ (19,773,114) $ (544,162)    
Basic net loss per share of Common Stock $ (0.04) $ (0.01) $ (0.43) $ (0.02)    
Diluted net loss per share of Common Stock $ (0.04) $ (0.01) $ (0.43) $ (0.02)    
Weighted average shares outstanding of Common Stock, basic 49,525,970 27,601,767 45,658,696 27,595,533    
Weighted average shares outstanding of Common Stock, diluted 49,525,970 27,601,767 45,658,696 27,595,533    
Aspire Biopharma Inc [Member]            
REVENUE            
Gross Receipts        
Net revenue        
COST OF REVENUE            
Cost of goods sold        
Total cost of revenue        
Gross Profit        
OPERATING EXPENSES            
Research and development         144,356 72,050
Sales and marketing         126,094 39,644
General and administrative expenses         940,421 246,895
Total operating expenses         1,210,871 358,589
Other income (expense):            
Interest expense         (97,988)
Total other (expense) income, net         (97,988)
Net gain/(loss) before income tax provision         (1,308,859) (358,589)
Income tax expense         1,013 481
Net loss         $ (1,309,872) $ (359,070)
Basic net loss per share of Common Stock         $ (0.003) $ (0.001)
Diluted net loss per share of Common Stock         $ (0.003) $ (0.001)
Weighted average shares outstanding of Common Stock, basic         507,353,659 481,794,521
Weighted average shares outstanding of Common Stock, diluted         507,353,659 481,794,521